Infliximab is a monoclonal anti–tumor necrosis factor (TNF)-α antibody indicated in steroid-resistant and/or fistulizing Crohn disease (CD). Reactivation of chronic viral hepatitis as well as opportunistic infections have been reported as adverse effects,1,2 but the impact of such drugs on patients' virological and immunological status remains unknown.3
Human immunodeficiency virus viral load and CD4+ T-cell count after infliximab therapy. A, Kinetics of both viral load and CD4+ T-cell count are indicated from 15 months before infliximab infusion, at the end of antiretroviral treatment, and 12 months after the treatment (x-axis), the latter showing an association with a dramatic decrease of both biological parameters over the period of anti–tumor necrosis factor treatment. Arrows indicate treatment infusions. B, We used a 4-staining cytofluorometric technique: T-cell subsets were recognized among CD45+ cells, using CD3–fluorescein isothiocyanate staining. Percentage of positive cells are indicated for each quadrant. C, A computer-assisted DNA histogram for CD4+ T cells (gate 1) and CD8 T cells (gate 2) separated by immunofluorescence analysis. Apoptotic cells manifested as a peak displaying reduced fluorescence. D, Kinetics of CD86 expression on monocytes in the patient and 12 healthy controls (triangles). APC indicates antigen-presenting cell; MIF, mean intensity fluorescence; PE, phycoerythrin.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.